# Codetta Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/codetta-bio

- Industry: Biotechnology
- Headquarters: Morrisville, US
- Website: www.codettabio.com
- Total disclosed funding: $15M
- Latest round: Series A (Apr 7, 2022)
- Investors on record: 3

## About

Based in North Carolina, US, and founded in 2021, Codetta Bio, Inc., doing business as Codetta™ Biosciences is a life sciences company that is developing a novel multi-omic analysis platform based on digital spatial polymerase chain reaction (dsPCR) and digital spatial immuno polymerase chain reaction (dsiPCR). In April 2022, Codetta Bio, Inc. raised USD 15 million in Series A funding led by new investor Anzu Partners, with participation from other new investors Genoa Ventures and VC23. As of June 2022, TJ Johnson is leading the firm as its CEO.

Codetta provides a digital spatial PCR platform that enables simultaneous, multiplexed, and multi-omic analyses of liquid biopsy and isolated DNA, RNA, and protein from single specimen to help develop next-generation therapies to improve patient care and quality of life. 

The company intends to use the April 2022 funding to accelerate the development of its multi-omic dsPCR platform and scale up the workforce in R&D, engineering, marketing, and business administration.

## Funding rounds

- Series A, Apr 7, 2022, $15M — Genoa Ventures, Anzu Partners, VC23

## Investors

- Genoa Ventures (https://capitalatlas.ai/funds/genoa-ventures) — Series A
- Anzu Partners (https://capitalatlas.ai/funds/anzu-partners) — Series A
- VC23 (https://capitalatlas.ai/funds/vc23) — Series A